Insights on the Protein Therapeutics Global Market to 2027 – Potential for Bispecific Monoclonal Antibodies Presents Opportunities

DUBLIN, April 11, 2022–(BUSINESS WIRE)–That “Protein Therapeutics Market Research Report by Protein Function (Enzymatic & Regulatory, Protein Diagnostics & Vaccines), Product Type, Region (Americas, Asia Pacific & Europe, Middle East & Africa) – Global Forecast to 2027 – Cumulative Impact of COVID -19” Report has been added ResearchAndMarkets.com Offer.

The size of the global protein therapeutics market has been estimated at US$67.83 billion in 2021 and US$73.00 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.80% by 2027 to reach $106.45 billion.

Cumulative Impact of the 2022 Russia-Ukraine Conflict:

We continuously monitor and update reports of political and economic uncertainties due to the Russian invasion of Ukraine. Negative impacts are clearly foreseen worldwide, particularly in Eastern Europe, the European Union, East and Central Asia and the United States.

This dispute has severely impacted lives and livelihoods and represents wide-ranging disruptions in trade dynamics. The potential impact of the ongoing war and uncertainty in Eastern Europe is expected to have a negative impact on the global economy, with particularly long-term harsh implications for Russia.

This report uncovers the impact of supply and demand, pricing variations, strategic vendor intake and recommendations for the Protein Therapeutics market considering the current update of the conflict and its global response.

Competitive strategic window:

The Competitive Strategic Window analyzes the competitive landscape in terms of markets, applications and regions to help the vendor define an alignment or match between its capabilities and opportunities for future growth prospects. It describes the optimal or favorable suitability for vendors to adopt sequential merger and acquisition strategies, geographic expansion, research and development, and new product launch strategies to conduct further business expansion and growth during a forecast period.

FPNV positioning matrix:

The FPNV Positioning Matrix evaluates and categorizes protein therapeutics market vendors based on business strategy (business growth, industry coverage, financial viability, and channel support) and product satisfaction (value for money, ease of use, product features, and customer support). ) that helps companies make better decisions and understand the competitive landscape.

Market share analysis:

Market share analysis offers the analysis of vendors considering their contribution to the overall market. It conveys the idea of ​​its revenue generation compared to other providers in this space in the overall market. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing the market share provides an idea of ​​the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance and merger characteristics.

The report answers questions like:

1. What is the market size and forecast of the global protein therapeutics market?

2. What are the restraining factors and impact of COVID-19 shaping the global protein therapeutics market during the forecast period?

3. What products/segments/applications/areas in the global protein therapeutics market to invest in during the forecast period?

4. What is the competitive strategic window for opportunities in the global protein therapeutics market?

5. What are the technology trends and regulatory framework in the global protein therapeutics market?

6. What is the market share of the leading vendors in the global protein therapeutics market?

7. What modes and strategic moves are considered suitable for entering the global protein therapeutics market?

market dynamics

driver

  • Rising healthcare spending in emerging markets

  • Government initiatives to improve health care

  • Growing geriatric population and increasing predominance of chronic diseases

limitations

  • Limitations for protein therapeutics such as high production costs and large proteins with low efficiency to enter tissues

  • Due to the denaturation in the intestine, the availability as an oral drug is problematic

occasions

challenges

companies mentioned

  • Ambrx

  • Araviv

  • Astra Zeneca PLC

  • Atomwise

  • car loop

  • DesigneRx Pharmaceuticals

  • medication dispensed

  • F. Hoffmann-La Roche AG

  • genetic engineering

  • Good therapeutics

  • Pastors Institute

  • LabGenius

  • Medicine at the University of Leiden

  • LGC Group

  • Morphic therapeutic

  • Omer

  • Pfizer

  • Protein Qure

  • Sanofi SA

  • SilkTech Biopharmaceuticals

  • translate bio

  • Trinity College Dublin

  • Venturis Therapeutics

For more information about this report, see https://www.researchandmarkets.com/r/hwybx7

View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005793/en/

contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For EST office hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours, call +353-1-416-8900

Leave a Comment